GAITHERSBURG, Md., May 21, 2024
/PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma"
or the "Company"), a global biopharmaceutical company dedicated to
discovering, developing, manufacturing, and delivering new
generations of vaccines and therapeutic biologics for infectious
diseases and cancer, today announced the results of its
extraordinary general meeting (the "EGM") held on May 21, 2024 in Hong
Kong. Each of the following resolutions was passed at the
EGM:
- As a special resolution that, the name of the Company be and
hereby is changed from YS Biopharma Co., Ltd. to LakeShore
Biopharma Co., Ltd (the "Proposed Change of Name"), and that any
one or more of the directors or the secretary of the Company be and
is/are hereby authorized to do all such acts and things and execute
all such documents as he/she/they may consider necessary, desirable
or expedient for the purpose of or in connection with, the
implementation of and giving effect to the Proposed Change of Name
and to attend to any necessary registration and/or filing for and
on behalf of the Company;
- As an ordinary resolution that, each of Dave Chenn,
Chunyang Shao, Zengjun Xu, Thomas
Xue and Adam Zhao, whose
biographic information is included in Exhibit A to the form of
proxy, be appointed as a director of the Company and that the
registered office service provider of the Company be and hereby is
authorized to update the Register of Directors and Officers of the
Company to reflect the above appointments and to file the updated
Register of Directors and Officers with the Registrar of Companies
in the Cayman Islands;
- As an ordinary resolution that, the 2024 Share Incentive Plan
in the form attached as Exhibit B to the form of proxy for
shareholders and approved by the resolutions of the board of
directors of the Company on May 2,
2024 be and hereby is approved and confirmed, and where
necessary ratified in all respects;
- As an ordinary resolution that, the resolutions passed at the
extraordinary general meeting of the shareholders of the Company
held on February 22, 2024 are hereby
reaffirmed, ratified and confirmed in all respects;
- As an ordinary resolution that, each director or officer of the
Company be and is hereby authorized to take any and every action
that might be necessary, appropriate or desirable to effect the
foregoing resolutions as such director or officer, in his or her
absolute discretion, thinks fit.
The Company is attending to the necessary filings with the
Registrar of Companies in Cayman
Islands to reflect the change of company name and director
appointments. In addition, the Company is working with the Nasdaq
Stock Market LLC to change the trading symbols of its ordinary
shares and warrants.
About YS Biopharma
YS Biopharma is a global biopharmaceutical company
dedicated to discovering, developing, manufacturing, and delivering
new generations of vaccines and therapeutic biologics for
infectious diseases and cancer. It has developed a proprietary
PIKA® immunomodulating technology platform and a
new generation of preventive and therapeutic biologics targeting
Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other
virus infections. YS Biopharma operates in China, the United
States, Singapore, and
the Philippines, and is led by a
management team that combines rich local expertise and global
experience in the biopharmaceutical industry. For more information,
please visit investor.ysbiopharma.com.
Investor Relations Contact
Alyssa Li
Director of Investor Relations
Email: ir@yishengbio.com
Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: YSBiopharma.IR@icrinc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ys-biopharma-announces-results-of-extraordinary-general-meeting-302151701.html
SOURCE YS Biopharma Co., Ltd.
